The overall goal of this project is to explore new strategies for more effective treatment of breast carcinoma and multiple myeloma based on modulating signal transduction pathways. Signal transducers and activators of transcription (STATs) are transcription factors that were discovered as key signaling components involved in mediating responses to cytokine stimulation. More recently, evidence has been accumulating that points to the involvement of STAT proteins in oncogenesis. We previously made the original observations that one STAT family member, STAT3 is constitutively activated in fibroblast cell lines transformed by the Src oncoprotein and is required for cell transformation. In addition, STAT3 is constitutively activated in fibroblast cell lines transformed by the Src oncoprotein and is required for cell transformation. In addition, STAT3 signaling is constitutively activate din fibroblast cell lines transformed by the Src oncoprotein and is required for cell transformation. In addition, STAT3 signaling is constitutively activated with high frequency in cell lines and tumor specimens of patients with breast cancer as well as the blood malignancy, multiple myeloma. We have shown that STAT3 signaling confers resistance in apoptosis in human myeloma tumor cells, providing evidence that STAT3 participates in malignant progression of this tumor by preventing programmed cell death. Moreover, another consequence of this anti-apoptotic activity of STAT3 may be to confer resistance to chemotherapy. In this project, we propose to test the hypothesis that STAT3 signaling participates in malignant progression of human cancer through regulation that also induce resistance to chemotherapy. This goal will be pursued through the following specific aims: (1) To define the mechanisms by which activated STAT3 signaling contributes to malignant transformation of breast carcinoma cells. (3) To determine if increasing levels of STAT3 activation are associated with malignant progression of multiple myeloma and acquisition of chemotherapy resistant in patients. (4) To develop new therapies for breast carcinoma and multiple myeloma based on pharmacologic approaches to inhibiting STAT3 signaling in animal models. In later years of this project, the basic mechanistic studies and clinical studies will be extended to ovarian cancer and acute myelogenous leukemia in order to assess the generality of our findings. Results of these studies will further define the role of activated STAT signaling in oncogenesis and evaluated new strategies for more effective therapy of human cancers that harbor activated STAT proteins.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA082533-01A1
Application #
6401795
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-05-01
Project End
2005-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of South Florida
Department
Type
DUNS #
City
Tampa
State
FL
Country
United States
Zip Code
33612
Daud, Adil I; Dawson, Jana; DeConti, Ronald C et al. (2009) Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 15:2479-87
Shain, Kenneth H; Yarde, Danielle N; Meads, Mark B et al. (2009) Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69:1009-15
Turner, Joel G; Marchion, Douglas C; Dawson, Jana L et al. (2009) Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 69:6899-905
Vultur, Adina; Buettner, Ralf; Kowolik, Claudia et al. (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7:1185-94
Buettner, Ralf; Huang, Mei; Gritsko, Tanya et al. (2007) Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 5:823-32
Nam, Sangkil; Williams, Ann; Vultur, Adina et al. (2007) Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 6:1400-5
Gritsko, Tanya; Williams, Ann; Turkson, James et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12:11-9
Turner, Joel G; Gump, Jana L; Zhang, Chunchun et al. (2006) ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108:3881-9
Song, Lanxi; Morris, Mark; Bagui, Tapan et al. (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66:5542-8
Simon, George R; Lush, Richard M; Gump, Jana et al. (2006) Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther 5:2130-7

Showing the most recent 10 out of 40 publications